MedWatch

Novo invests heavily in Danish manufacturing

The Danish diabetes giant, Novo Nordisk, is ready with a new large investment in its home country, which will create jobs in the town Kalundborg.

Foto: Novo Nordisk/PR

Novo Nordisk is now investing DKK 380 million (USD 67 million) in an overhaul of its manufacturing facilities in its factory in the Danish town Kalundborg, in order to produce a new type II diabetes drug, semaglutid, the company reveals.

“The investment in Kalundborg highlights our long-term ambition to create and maintain jobs in Denmark. This year alone, Novo Nordisk has created 100 new jobs in Kalundborg and we are always looking for skilled and well-trained people,” says Per Valstorp, head of manufacturing in Novo Nordisk.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier